Latest & greatest articles for anticoagulation

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on anticoagulation or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on anticoagulation and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for anticoagulation

101. Thromboembolic outcomes of different anticoagulation strategies for patients with atrial fibrillation in the setting of hypertrophic cardiomyopathy: a systematic review and meta-analysis

Thromboembolic outcomes of different anticoagulation strategies for patients with atrial fibrillation in the setting of hypertrophic cardiomyopathy: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility

2019 PROSPERO

102. What is the clinical and cost effectiveness of discontinuing anticoagulation in people whose atrial fibrillation has resolved?

What is the clinical and cost effectiveness of discontinuing anticoagulation in people whose atrial fibrillation has resolved? Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2019 PROSPERO

103. Efficacy and safety of direct oral anticoagulants versus low-molecular-weight heparin in patients with cancer: a systematic review and meta-analysis

Efficacy and safety of direct oral anticoagulants versus low-molecular-weight heparin in patients with cancer: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

104. Comparing the risk of intracranial bleeding in seniors who fall on anticoagulation, antiplatelet medication or no antithrombotic medication

Comparing the risk of intracranial bleeding in seniors who fall on anticoagulation, antiplatelet medication or no antithrombotic medication Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration

2019 PROSPERO

105. Direct oral anticoagulant (DOAC) versus placebo for the prevention of thrombosis in ambulatory patients with cancer at increased risk: a systematic review and meta-analysis

Direct oral anticoagulant (DOAC) versus placebo for the prevention of thrombosis in ambulatory patients with cancer at increased risk: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability

2019 PROSPERO

106. Anticoagulants for the treatment of venous thromboembolism in patients with cancer: a pairwise and network meta-analysis of randomized trials

Anticoagulants for the treatment of venous thromboembolism in patients with cancer: a pairwise and network meta-analysis of randomized trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

107. Bleeding risk and history of comorbidities in patients with atrial fibrillation treated with oral anticoagulation: a meta-analysis

Bleeding risk and history of comorbidities in patients with atrial fibrillation treated with oral anticoagulation: a meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record

2019 PROSPERO

108. Extracorporeal membrane oxygenation without therapeutic anticoagulation in adult patients: a systematic review of the current literature

Extracorporeal membrane oxygenation without therapeutic anticoagulation in adult patients: a systematic review of the current literature Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration

2019 PROSPERO

109. Safety and efficacy of anticoagulant and antiplatelet combination treatment strategies in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention: a network meta-analysis of randomized clinical trials

Safety and efficacy of anticoagulant and antiplatelet combination treatment strategies in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention: a network meta-analysis of randomized clinical trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied

2019 PROSPERO

110. Non-vitamin K antagonist oral anticoagulants versus warfarin in patients with cancer and atrial fibrillation: a systematic review and meta-analysis

Non-vitamin K antagonist oral anticoagulants versus warfarin in patients with cancer and atrial fibrillation: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

111. Drug-drug interactions of novel (direct) oral anticoagulants in clinical settings - a systematic review

Drug-drug interactions of novel (direct) oral anticoagulants in clinical settings - a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

112. Direct oral anticoagulant compared to low molecular weight heparin in the treatment of venous thromboembolism in patients with cancer: a systematic review and meta-analysis of randomized controlled trials

Direct oral anticoagulant compared to low molecular weight heparin in the treatment of venous thromboembolism in patients with cancer: a systematic review and meta-analysis of randomized controlled trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears

2019 PROSPERO

113. Anticoagulation control in patients on vitamin K antagonists in Africa: a systematic review

Anticoagulation control in patients on vitamin K antagonists in Africa: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external

2019 PROSPERO

114. Adherence and persistence to direct oral anticoagulants in patients with atrial fibrillation

Adherence and persistence to direct oral anticoagulants in patients with atrial fibrillation Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external

2019 PROSPERO

115. Specialized anticoagulation management service care compared with no specialized anticoagulation management service care provided by the patient's physician for patients receiving anticoagulation therapy: systematic review and meta-analysis

Specialized anticoagulation management service care compared with no specialized anticoagulation management service care provided by the patient's physician for patients receiving anticoagulation therapy: systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission

2019 PROSPERO

116. Safety and efficacy of direct oral anticoagulants in cancer patient with atrial fibrillation. A systematic review and meta-analysis

Safety and efficacy of direct oral anticoagulants in cancer patient with atrial fibrillation. A systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record

2019 PROSPERO

117. What is the most clinically and cost-effective anticoagulant therapy for stroke prevention in people with atrial fibrillation?

What is the most clinically and cost-effective anticoagulant therapy for stroke prevention in people with atrial fibrillation? Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2019 PROSPERO

118. Medication errors associated with non-vitamin K antagonist oral anticoagulants (NOACs) in adult patients

Medication errors associated with non-vitamin K antagonist oral anticoagulants (NOACs) in adult patients Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

119. Non-vitamin K antagonist oral anticoagulants for cancer associated thrombosis: are there differences between real-world practice and trials? A critical systematic review and meta-analysis

Non-vitamin K antagonist oral anticoagulants for cancer associated thrombosis: are there differences between real-world practice and trials? A critical systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility

2019 PROSPERO

120. Adherence to oral anticoagulants for treatment of atrial fibrillation in the Middle East: a systematic review

Adherence to oral anticoagulants for treatment of atrial fibrillation in the Middle East: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO